troglitazone has been researched along with Necrosis in 8 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Necrosis: The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.
| Excerpt | Relevance | Reference |
|---|---|---|
| "An autopsy case of fatal subacute hepatic failure after administration of troglitazone is described." | 7.70 | Subacute hepatic failure associated with a new antidiabetic agent, troglitazone: a case report with autopsy examination. ( Adachi, H; Amano, S; Bamba, T; Fujiyama, Y; Fukano, M; Okabe, H; Sato, J; Yamamoto, K, 2000) |
| "Troglitazone (TZ) is a synthetic ligand of peroxisome proliferator-activated receptor-γ, and it can induce apoptosis and autophagy in a variety of cancer cells." | 5.40 | The PPARγ agonist Troglitazone induces autophagy, apoptosis and necroptosis in bladder cancer cells. ( Chen, T; Jiang, X; Xi, Z; Yan, S; Yang, X, 2014) |
| "Troglitazone does not cause hepatotoxicity in normal healthy rodents, but it produces mitochondrial injury in vitro at high concentrations." | 5.34 | Troglitazone-induced hepatic necrosis in an animal model of silent genetic mitochondrial abnormalities. ( Boelsterli, UA; Latchoumycandane, C; Ong, MM, 2007) |
| "Here, we demonstrate that troglitazone (Rezulin), a peroxisome proliferator-activated receptor agonist, acted in synergy with heregulin to induce massive cell death in breast cancer cells." | 3.77 | Synergistic interactions between heregulin and peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist in breast cancer cells. ( Lee, BC; Lee, SB; Lee, YJ; Park, BH; Stolz, DB, 2011) |
| "Recently, it was reported that the intraperitoneal administration of 30 mg/kg/day troglitazone to heterozygous superoxide dismutase 2 gene knockout (Sod2+/-) mice for twenty-eight days caused liver injury, manifested by increased serum ALT activity and hepatic necrosis." | 3.75 | Sensitivity of liver injury in heterozygous Sod2 knockout mice treated with troglitazone or acetaminophen. ( Ando, Y; Arakawa, S; Fujimoto, K; Ito, K; Kumagai, K; Manabe, S; Oda, S; Yamoto, T, 2009) |
| "An autopsy case of fatal subacute hepatic failure after administration of troglitazone is described." | 3.70 | Subacute hepatic failure associated with a new antidiabetic agent, troglitazone: a case report with autopsy examination. ( Adachi, H; Amano, S; Bamba, T; Fujiyama, Y; Fukano, M; Okabe, H; Sato, J; Yamamoto, K, 2000) |
| "Troglitazone (TZ) is a synthetic ligand of peroxisome proliferator-activated receptor-γ, and it can induce apoptosis and autophagy in a variety of cancer cells." | 1.40 | The PPARγ agonist Troglitazone induces autophagy, apoptosis and necroptosis in bladder cancer cells. ( Chen, T; Jiang, X; Xi, Z; Yan, S; Yang, X, 2014) |
| "Troglitazone does not cause hepatotoxicity in normal healthy rodents, but it produces mitochondrial injury in vitro at high concentrations." | 1.34 | Troglitazone-induced hepatic necrosis in an animal model of silent genetic mitochondrial abnormalities. ( Boelsterli, UA; Latchoumycandane, C; Ong, MM, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (75.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yan, S | 1 |
| Yang, X | 1 |
| Chen, T | 1 |
| Xi, Z | 1 |
| Jiang, X | 2 |
| Zhang, W | 1 |
| Meng, X | 1 |
| Yan, J | 1 |
| Fujimoto, K | 1 |
| Kumagai, K | 1 |
| Ito, K | 1 |
| Arakawa, S | 1 |
| Ando, Y | 1 |
| Oda, S | 1 |
| Yamoto, T | 1 |
| Manabe, S | 1 |
| Park, BH | 1 |
| Lee, SB | 1 |
| Stolz, DB | 1 |
| Lee, YJ | 1 |
| Lee, BC | 1 |
| Watkins, PB | 1 |
| Ong, MM | 1 |
| Latchoumycandane, C | 1 |
| Boelsterli, UA | 1 |
| Soller, M | 1 |
| Dröse, S | 1 |
| Brandt, U | 1 |
| Brüne, B | 1 |
| von Knethen, A | 1 |
| Fukano, M | 1 |
| Amano, S | 1 |
| Sato, J | 1 |
| Yamamoto, K | 1 |
| Adachi, H | 1 |
| Okabe, H | 1 |
| Fujiyama, Y | 1 |
| Bamba, T | 1 |
8 other studies available for troglitazone and Necrosis
| Article | Year |
|---|---|
The PPARγ agonist Troglitazone induces autophagy, apoptosis and necroptosis in bladder cancer cells.
Topics: Adenylate Kinase; Apoptosis; Autophagy; Blotting, Western; Cell Line, Tumor; Chromans; Humans; Necro | 2014 |
[Stimulating autophagosome formation and inducing mixed cell death in HeLa cells by troglitazone].
Topics: Animals; Autophagy; Blotting, Western; Chromans; Flow Cytometry; Gene Expression Regulation; HeLa Ce | 2008 |
Sensitivity of liver injury in heterozygous Sod2 knockout mice treated with troglitazone or acetaminophen.
Topics: Acetaminophen; Adenosine Triphosphate; Alanine Transaminase; Alkaline Phosphatase; Animals; Aspartat | 2009 |
Synergistic interactions between heregulin and peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist in breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Chromans; Drug Synergism; Fema | 2011 |
Idiosyncratic liver injury: challenges and approaches.
Topics: Adaptation, Physiological; Chemical and Drug Induced Liver Injury, Chronic; Chromans; Humans; Hypogl | 2005 |
Troglitazone-induced hepatic necrosis in an animal model of silent genetic mitochondrial abnormalities.
Topics: Aconitate Hydratase; Animals; Chemical and Drug Induced Liver Injury; Chromans; Disease Models, Anim | 2007 |
Mechanism of thiazolidinedione-dependent cell death in Jurkat T cells.
Topics: Adenosine Triphosphate; Apoptosis; Cell Death; Cell Line, Tumor; Cell Survival; Chromans; Humans; Ju | 2007 |
Subacute hepatic failure associated with a new antidiabetic agent, troglitazone: a case report with autopsy examination.
Topics: Chromans; Diabetes Mellitus, Type 2; Fatal Outcome; Female; Humans; Hypoglycemic Agents; Liver Failu | 2000 |